Patents by Inventor Mark J. Wall
Mark J. Wall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190345214Abstract: The present invention comprises compounds of Formula I. wherein: Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.Type: ApplicationFiled: October 26, 2017Publication date: November 14, 2019Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Mark J. WALL, Yue-Mei ZHANG
-
Publication number: 20190330296Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.Type: ApplicationFiled: April 24, 2019Publication date: October 31, 2019Inventors: Yue-Mei ZHANG, Raul C. CAMACHO, Martin A. CASE, Ellen CHI, Suzanne EDAVETTAL, Wilson EDWARDS, Lisa NORQUAY, Mark J. WALL, Rui ZHANG, Songmao ZHENG
-
Publication number: 20190298849Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.Type: ApplicationFiled: October 26, 2017Publication date: October 3, 2019Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Shamina M. RANGWALA, James N. LEONARD, Raul C. CAMACHO, Michael J. HUNTER, Katharine E. D'AQUINO, Wilson EDWARDS, Ronald V. SWANSON, Wenying JIAN, Yue-Mei ZHANG, Mark J. WALL, Ellen CHI
-
Publication number: 20190263879Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.Type: ApplicationFiled: October 26, 2017Publication date: August 29, 2019Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Mark J. WALL, Yue-Mei ZHANG, Shamina M. RANGWALA, James N. LEONARD, Raul C. CAMACHO, Michael J. HUNTER, Katharine E. D'AQUINO, Wilson EDWARDS, Ronald V. SWANSON, Wenying JIAN, Ellen CHI
-
Patent number: 10077241Abstract: The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, R6, R7, R8, X, Z1 and Z2 are defined in the specification.Type: GrantFiled: April 14, 2015Date of Patent: September 18, 2018Assignee: Jansen Pharmaceutica NVInventors: Xuqing Zhang, Mark J. Wall, Zhihua Sui
-
Publication number: 20170029381Abstract: The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, R6, R7, R8, X, Z1 and Z2 are defined in the specification.Type: ApplicationFiled: April 14, 2015Publication date: February 2, 2017Inventors: Xuqing Zhang, Mark J. Wall, Zhihua Sui
-
Patent number: 9526731Abstract: A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.Type: GrantFiled: December 8, 2014Date of Patent: December 27, 2016Assignee: Janssen Pharmaceutica NVInventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Sanath K. Meegalla, M. Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee Louise Desjarlais, Carl M. Manthey, Christopher J. Molloy
-
Publication number: 20150094520Abstract: A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.Type: ApplicationFiled: December 8, 2014Publication date: April 2, 2015Inventors: Carl R. ILLIG, Shelley K. BALLENTINE, Jinsheng CHEN, Sanath K. MEEGALLA, M. Jonathan RUDOLPH, Mark J. WALL, Kenneth J. WILSON, Renee Louise DESJARLAIS, Carl M. MANTHEY, Christopher J. MOLLOY
-
Patent number: 8933091Abstract: A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.Type: GrantFiled: September 6, 2013Date of Patent: January 13, 2015Assignee: Janssen Pharmaceutica NVInventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Sanath K. Meegalla, M. Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee Louise Desjarlais, Carl M. Manthey, Christopher J. Molloy
-
Patent number: 8697716Abstract: A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.Type: GrantFiled: April 19, 2007Date of Patent: April 15, 2014Assignee: Janssen Pharmaceutica NVInventors: Carl R. Illig, Shelley K. Balltentine, Jinsheng Chen, Sanath K. Meegalla, M. Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee L. DesJarlais, Carl L. Manthey, Christopher J. Molloy
-
Publication number: 20140005225Abstract: A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.Type: ApplicationFiled: September 6, 2013Publication date: January 2, 2014Applicant: Janssen Pharmaceutica NVInventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Sanath K. Meegalla, M. Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee Louise Desjarlais, Carl M. Manthey, Christopher J. Molloy
-
Patent number: 8497376Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.Type: GrantFiled: October 16, 2008Date of Patent: July 30, 2013Assignee: Janssen Pharmaceutica N.V.Inventors: Carl R. Illig, Jinsheng Chen, Sanath K. Meegalia, Mark J. Wall
-
Patent number: 7795279Abstract: A method of reducing or inhibiting kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.Type: GrantFiled: October 17, 2006Date of Patent: September 14, 2010Assignee: Janssen Pharmaceutica NVInventors: Shelley K. Ballentine, Christian Andrew Baumann, Jinsheng Chen, Carl R. Illig, Sanath K. Meegalla, M. Jonathan Rudolph, Robert W. Tuman, Mark J. Wall, Kenneth Wilson, Dana L. Johnson
-
Patent number: 7705042Abstract: The invention relates to arylamide and hetereoarylamide compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.Type: GrantFiled: October 20, 2005Date of Patent: April 27, 2010Assignee: Janssen Pharmaceutica NVInventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Sanath Meegalla, Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee DesJarlais, Carl L. Manthey, Christopher M. Flores, Christopher J. Molloy
-
Patent number: 7662837Abstract: The invention is directed to compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.Type: GrantFiled: October 20, 2005Date of Patent: February 16, 2010Assignee: Janssen Pharmaceutica N.V.Inventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Sanath K. Meegalla, M. Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee L. Desjarlais, Carl L. Manthey, Christopher Flores, Christopher J. Molloy
-
Patent number: 7645755Abstract: The invention is directed to compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.Type: GrantFiled: April 20, 2006Date of Patent: January 12, 2010Assignee: Janssen Pharmaceutical N.V.Inventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Sanath K. Meegalla, M. Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee L. Desjarlais, Carl L. Manthey, Christopher Flores, Christopher J. Molloy
-
Publication number: 20090105296Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.Type: ApplicationFiled: October 16, 2008Publication date: April 23, 2009Inventors: Carl R. Illig, Jinsheng Chen, Sanath K. Meegalia, Mark J. Wall
-
Patent number: 7326788Abstract: The invention is directed to compounds of Formulae I and II: wherein R1, R2, R3, R5, R6, Y1, Y2, Y3, Y4 and X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.Type: GrantFiled: July 20, 2004Date of Patent: February 5, 2008Assignee: Janssen Pharmaceutica N.V.Inventors: Mark J. Wall, Mark R. Player, Raymond Joseph Patch, Sanath Meegalla, Jian Liu, Carl R. Illig, Wing Cheung, Jinsheng Chen, Davoud Asgari